170 related articles for article (PubMed ID: 34772582)
21. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Shih Y; Chen S; Huang J; Chen Y; Zhu Z; Zhao Q; Zhao X; Xue F; Xiang J; Chen X; Zhu X; Pan M; Wu J; Zheng J; Li H; Cao H
Rheumatology (Oxford); 2024 Jan; 63(1):251-258. PubMed ID: 37184873
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.
Muro Y; Sugiura K; Akiyama M
Clin Rev Allergy Immunol; 2016 Dec; 51(3):293-302. PubMed ID: 26100618
[TBL] [Abstract][Full Text] [Related]
23. Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis.
Konishi R; Ichimura Y; Tanaka R; Miyahara H; Okune M; Miyamoto M; Hara M; Iwabuchi A; Takada H; Nakagishi Y; Mizuta M; Kaneko S; Shimizu M; Morio T; Nishino I; Nomura T; Okiyama N
Immunol Med; 2024 Jun; 47(2):100-105. PubMed ID: 38174692
[TBL] [Abstract][Full Text] [Related]
24. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
[TBL] [Abstract][Full Text] [Related]
25. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
26. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
27. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
28. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.
Shimizu T; Tomita Y; Son K; Nishinarita S; Sawada S; Horie T
Clin Rheumatol; 2000; 19(5):352-9. PubMed ID: 11055823
[TBL] [Abstract][Full Text] [Related]
29. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
30. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
32. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis.
Kryštůfková O; Hulejová H; Mann HF; Pecha O; Půtová I; Ekholm L; Lundberg IE; Vencovský J
Arthritis Res Ther; 2018 Jul; 20(1):158. PubMed ID: 30053824
[TBL] [Abstract][Full Text] [Related]
34. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
35. Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy.
Ebrahimi M; Rostamian A; Rafiei-Latianee R; Najafizadeh SR; Movaseghi S; Faezi ST; Ghazanfari T
Clin Rheumatol; 2022 Feb; 41(2):533-539. PubMed ID: 34514533
[TBL] [Abstract][Full Text] [Related]
36. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
37. Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis.
Li L; Liu C; Wang Q; Wu C; Zhang Y; Cheng L; Wen X; Zeng X; Zhang F; Li Y
J Clin Lab Anal; 2020 Aug; 34(8):e23307. PubMed ID: 32222002
[TBL] [Abstract][Full Text] [Related]
38. TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis.
Cordel N; Derambure C; Coutant S; Mariette X; Jullien D; Debarbieux S; Chosidow O; Meyer A; Bessis D; Joly P; Mathian A; Levesque H; Sabourin JC; Tournier I; Boyer O;
Rheumatology (Oxford); 2021 Dec; 60(12):5863-5867. PubMed ID: 33764396
[TBL] [Abstract][Full Text] [Related]
39. Anti-TIF1gamma Antibody-Positive Dermatomyositis Associated with Myelodysplastic Syndrome: Response to Treatment.
Lerman I; Richardson CT
Cureus; 2019 Sep; 11(9):e5775. PubMed ID: 31723534
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
